Lineage, Inc. Common Stock (LINE)vsVuzix Corp Cmn Stk (VUZI)
LINE
Lineage, Inc. Common Stock
$39.96
-0.03%
REAL ESTATE · Cap: $10.02B
VUZI
Vuzix Corp Cmn Stk
$3.11
+8.74%
TECHNOLOGY · Cap: $239.50M
Smart Verdict
WallStSmart Research — data-driven comparison
Lineage, Inc. Common Stock generates 85242% more annual revenue ($5.36B vs $6.28M). VUZI leads profitability with a 0.0% profit margin vs -2.7%. LINE earns a higher WallStSmart Score of 39/100 (F).
LINE
Hold39
out of 100
Grade: F
VUZI
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+75.9%
Fair Value
$161.27
Current Price
$39.96
$121.31 discount
Margin of Safety
+43.1%
Fair Value
$4.34
Current Price
$3.11
$1.23 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 76.3% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.4% revenue growth
0.0% earnings growth
Operating margin of 3.3%
ROE of -1.8% — below average capital efficiency
Trading at 10.4x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : LINE
The strongest argument for LINE centers on Price/Book.
Bull Case : VUZI
The strongest argument for VUZI centers on Revenue Growth, Debt/Equity. Revenue growth of 76.3% demonstrates continued momentum.
Bear Case : LINE
The primary concerns for LINE are Revenue Growth, EPS Growth, Operating Margin.
Bear Case : VUZI
The primary concerns for VUZI are Price/Book, EPS Growth, Market Cap.
Key Dynamics to Monitor
LINE profiles as a turnaround stock while VUZI is a hypergrowth play — different risk/reward profiles.
VUZI is growing revenue faster at 76.3% — sustainability is the question.
VUZI generates stronger free cash flow (-6M), providing more financial flexibility.
Monitor REIT - INDUSTRIAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LINE scores higher overall (39/100 vs 26/100). VUZI offers better value entry with a 43.1% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Lineage, Inc. Common Stock
REAL ESTATE · REIT - INDUSTRIAL · USA
Lineage, Inc. (Ticker: LINE) is a pioneering biotechnology firm focused on regenerative medicine, specifically developing cutting-edge cell therapy solutions for treating debilitating conditions, including ocular diseases, spinal cord injuries, and various cancers. With its proprietary technologies and robust network of strategic collaborations, Lineage is poised to transform patient care through innovative therapeutic interventions. The company's commitment to advancing its diverse product pipeline and expediting clinical research positions it as an attractive investment opportunity for institutional investors seeking to engage in the forefront of healthcare advancements.
Visit Website →Vuzix Corp Cmn Stk
TECHNOLOGY · CONSUMER ELECTRONICS · USA
Vuzix Corporation designs, manufactures, markets and sells augmented reality (AR) computing and display devices for consumer and business markets in North America, Asia-Pacific, Europe, and internationally. The company is headquartered in West Henrietta, New York.
Compare with Other REIT - INDUSTRIAL Stocks
Want to dig deeper into these stocks?